Implantation or Injectable Dosage Form New Animal Drugs; Trenbolone Acetate and Estradiol

FederalRegulations

Ask Donna

How this section applies to your facts.

Federal Register › Vol. 60 › 60 FR 4375

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs;

Trenbolone Acetate and Estradiol

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal

drug regulations to reflect approval of a new animal drug application

(NADA) filed by Roussel-Uclaf. The NADA provides for use of an ear

implant containing trenbolone acetate and estradiol for heifers fed in

confinement for slaughter for increased rate of weight gain and

improved feed efficiency.

EFFECTIVE DATE: January 23, 1995.

FOR FURTHER INFORMATION CONTACT: Jack Caldwell, Center for Veterinary

Medicine (HFV-126), Food and Drug Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301-594-1638.

SUPPLEMENTARY INFORMATION: Roussel-Uclaf, Division Agro-Veterinaire,

163 Avenue Gambetta, 75020, Paris, France, represented in the United

States by Hoechst-Roussel Agri-Vet Co., Rt. 202-206, P.O. Box 2500,

Somerville, NJ 08876-1258, filed NADA 140-992 which provides for use of

an ear implant containing 7 pellets, each pellet containing 20

milligrams (mg) of trenbolone acetate and 2 mg of estradiol. The

implant is used in heifers fed in confinement for slaughter for

increased rate of weight gain and improved feed efficiency. The NADA is

approved as of December 13, 1994, and the regulations are amended in 21

CFR 522.2477 to reflect the approval. The basis for approval is

discussed in the freedom of information summary.

In accordance with the freedom of information provisions of part 20

(21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a

summary of safety and effectiveness data and information submitted to

support approval of this application may be seen in the Dockets

Management Branch (HFA-305), Food and Drug Administration, rm. 1-23,

12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m.,

Monday through Friday.

Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and

Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for

a 3-year period of marketing exclusivity beginning on December 13,

1994, because new clinical or field investigations (other than

bioequivalence or residue studies), or human food safety studies (other

than bioequivalence or residue studies) essential to the approval were

conducted or sponsored by the applicant.

The agency has carefully considered the potential environmental

effects of this action. FDA has concluded that the action will not have

a significant impact on the human environment, and that an

environmental impact statement is not required. The agency's finding of

no significant impact and the evidence supporting that finding,

contained in an environmental assessment, may be seen in the Dockets

Management Branch (address above) between 9 a.m. and 4 p.m., Monday

through Friday.

List of Subjects in 21 CFR Part 522

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under

authority delegated to the Commissioner of Food and Drugs and

redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is

amended as follows:

PART 522--IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 522 continues to read as

follows:

Authority: Sec. 512 of the Federal Food, Drug, and Cosmetic Act

(21 U.S.C. 360b).

2. Section 522.2477 is revised to read as follows:

Sec. 522.2477 Trenbolone acetate and estradiol.

(a) Sponsor. See No. 012579 in Sec. 510.600(c) of this chapter.

(b) Related tolerances. See Secs. 556.240 and 556.739 of this

chapter.

(c) Conditions of use--(1) Feedlot steers--(i) Amount. 120

milligrams of trenbolone acetate and 24 milligrams of estradiol (6

pellets, each pellet containing 20 milligrams of trenbolone acetate and

4 milligrams of estradiol) per animal.

(ii) Indications for use. For increased rate of weight gain and

improved feed efficiency in feedlot steers.

(iii) Limitations. Implant subcutaneously in ear only. Do not use

in animals intended for subsequent breeding or in dairy animals.

(2) Heifers--(i) Amount. 140 milligrams of trenbolone acetate and

14 milligrams of estradiol (7 pellets, each pellet containing 20

milligrams of trenbolone acetate and 2 milligrams of estradiol) per

animal.

(ii) Indications for use. For increased rate of weight gain and

improved feed efficiency in heifers fed in confinement for slaughter.

(iii) Limitations. Implant subcutaneously in ear only. Do not use

in animals intended for subsequent breeding or in dairy animals.

Dated: January 13, 1995.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 95-1654 Filed 1-20-95; 8:45 am]

BILLING CODE 4160-01-F

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.